Keros Therapeutics Stock Discussion

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US)$  Phase 2
$Supernus Pharmaceuticals(SUPN.US)$  Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US)$  Phase 2a
$MorphoSys(MOR.US)$  Phase 2
$Nuvation Bio(NUVB.US)$  Phase 2
$ALX Oncology(ALXO.US)$  Phase 2
$BioXcel Therapeutics(BTAI.US)$  Phase 2
$Purple Biotech(PPBT.US)$  Phase 2
$Arcus Biosciences(RCUS.US)$  Phase 2
$Medicenna Therapeutics(MDNAF.US)$  Phase 2b
$Affimed NV(AFMD.US)$  Phase 2
$Barinthus Biotherapeutics(BRNS.US)$  Phase 2b...

NHP data from $Regeneron Pharmaceuticals(REGN.US)$ 's new slide deck is very relevant for the weight loss space.
Combining pure anti-Myostatin antibodies with Semaglutide was marginally effective in NHPs in preventing muscle loss. I believe that for that reason, $Scholar Rock(SRRK.US)$ and probably also $Biohaven(BHVN.US)$ are likely to disappoint.
Additionally blocking other ligands like Activin A dramatically improves body composition. That is what $Eli Lilly and Co(LLY.US)$ , $Keros Therapeutics(KROS.US)$ ...